Contact
Header_1077x260px_About_Profil.jpg

Pramlintide as adjunct therapy for the treatment of type 1 diabetes

Where are we today?

Insulin treatment for type 1 diabetes mellitus (T1D) has improved over the past decades due to advances in insulin formulations and administration techniques. Nevertheless, optimal glucose control and reaching HbA1c goals remain challenging for many patients. Consequently, the risk of subsequent micro- and macrovascular complications remains high and life expectancy is still reduced in this patient group so that there is an obvious need for improvement of current therapies or the development of new, additional treatments [1]. So what else can be done?

 

Read More

Topics: Treating Diabetes, Clinical Trials in Diabetes

Posted by Dr. Susanne Famulla on Dec 19, 2018 5:12:00 PM
dr-susanne-famulla

New strategies for the treatment of obesity and metabolic dysfunctions

Targeting the incretin/glucagon system with agonists

Figure 1: Schematic representation of the effects of multi-agonists targeting the receptors for GLP-1/Glucagon, GLP-1/GIP and GLP-1/GIP/Glucagon [28]

In Part I of our blog we reported on dual receptor agonists targeting the incretin/glucagon system to treat obesity and type 2 diabetes mellitus with high efficacy. So far, it has been recognized that the concept of combined targeting of gut hormone receptors is also working in humans [1, 2]. In Part II we will focus on the twincretins GIP and GLP-1 [3] to improve glycaemic control and the tri-agonists GLP-1/GIP/Glucagon to treat obesity, type 2 diabetes mellitus and hepatosteatosis [non-alcoholic steatohepatitis (NASH)].

Read More

Topics: Treating Diabetes

Posted by Dr. Ulrike Hövelmann on Nov 13, 2018 5:09:00 PM
dr-ulrike-hövelmann

Artificial Intelligence to Screen for Diabetic Retinopathy; The Times They Are A-Changin‘.

The far majority of clinical trials in diabetes exclude patients with active retinal disease, as interventions that lower glucose rapidly can temporarily worsen retinopathy. This was originally shown in type 1 diabetes [1] but more recently also in type 2 diabetes [2, 3]. Screening for diabetic retinopathy before inclusion in a clinical trial is relatively cumbersome, also because it often involves a separate visit to an ophthalmologist. The use of a fundus camera with offline interpretation by an ophthalmologist has gained widespread use in clinical practice, but not so much in the field of clinical trials.

In this blog I will briefly describe four recent studies on artificial intelligence approaches to automate the interpretation of retinal images. I will conclude with an outlook on how this may facilitate the screening of potential trial participants for diabetic retinopathy. But first a brief introduction to deep learning, the methodology applied in all these papers.

Read More

Topics: Treating Diabetes, The Science behind Diabetes, Diabetes Technology

Posted by Prof. Hans de Vries on Oct 23, 2018 5:18:00 PM
prof-hans-de-vries

54th EASD Annual Meeting – Profil’s contributions to the scientific sessions

Berlin, Germany, 1-5 October 2018

Last week our team joined an exciting and busy 54th EASD Annual Meeting in Berlin. We would like to give you a brief overview about those orals and posters presenting results from clinical trials Profil had been involved in.

Read More

Topics: Treating Diabetes, Diabetes Technology, The Science behind Diabetes

Posted by Dr. Sabine Arnolds on Oct 10, 2018 4:15:43 PM
dr-sabine-arnolds

Profil explores opportunities for artificial pancreas in type 2 diabetes

Highlighting the role of open and trans-sectoral collaboration in the advancement of artificial pancreas solutions

Profil has recently published a peer-reviewed article on the topic of “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project ” in the Journal of Diabetes Science and Technology. Profil is the organisation coordinating CLOSE. The article is authored by CLOSE industry and academic partners, representatives of the EIT Health public-private partnership management boards, and key opinion leaders in the field.

Read More

Topics: Treating Diabetes, Diabetes Technology, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Oct 2, 2018 5:18:00 PM
prof-dr-freimut-schliess

Work stress is the new smoking

According to the WHO, about 31% of all deaths worldwide (17.7 million deaths per year) [1] are attributable to cardiovascular disease (CVD), making CVDs the number 1 cause of death globally. Known risk factors for the development of CVD, among others, are smoking, high blood pressure or the lack of physical activity. Especially the latter has been discussed in the recent years and it became known that long hours of sitting [2] may increase your risk of CVD and diabetes (and may apparently even increase mortality, in the case of binge watching [3]). While numerous risk factors for CVD are known and several recommendations and guidelines on how to handle them exist, the prognostic role of what may possibly be one of the most common and important factors on cardiovascular health nowadays has not yet been formally assessed: stress at work.

Read More

Topics: Treating Diabetes, Clinical Trials in Diabetes

Posted by Dr. Theresa Herbrand on Sep 25, 2018 5:12:00 PM
dr-theresa-herbrand

Do-It-Yourself Artificial Pancreas systems (DIY APS)

The way forward to closed-loop metabolic control in diabetes care?

The challenge

Diabetes represents a huge and multidimensional challenge. Despite the availability of numerous treatment options, many patents still fail to reach their treatment goals. Administration of  the right amount of insulin at the right time still poses a great challenge for the self-management of many people with diabetes.

Accordingly there is a huge need to implement new innovative products and services improving both the effectiveness of diabetes care and the quality of life for people with diabetes. Particularly user-centered products and sercvices co-created with stakeholders including people with diabetes may have a high potential to increase treatment adherence thereby reducing the enormous pressure on healthcare systems.

Read More

Topics: Diabetes Technology, Treating Diabetes, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Sep 5, 2018 5:16:00 PM
prof-dr-freimut-schliess

Targeting the incretin/glucagon system: a glimmer of hope

Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy

The rising prevalence of obesity has metabolic consequences such as diabetes and cardiovascular complications. Many existing therapies for type 2 diabetes mellitus (T2DM) focus on lowering blood glucose; however, there is a major unmet need for treatments that both improve glycemic control and achieve metabolic benefits by weight loss. Lifestyle interventions, such as dieting and physical activity, typically provide only short-lasting weight loss in obese people, as weight loss maintenance is the greatest barrier to successful treatment of obesity [1].

 

Read More

Topics: Treating Diabetes

Posted by Dr. Ulrike Hövelmann on Aug 28, 2018 5:11:00 PM
dr-ulrike-hövelmann

Even moderate overweight increases the risk for cardiovascular disease, recent study says

A substantial amount of studies in the last decade have determined the detrimental effects of overweight and obesity on the risk of myocardial infarction, stroke, cancer, and overall mortality. Nonetheless, there is also evidence in favour of the so-called “obesity-paradox” which states that overweight - or even obesity - exerts a protective role or has no impact on the incidence of cardiovascular disease (CVD) and overall mortality, because of increased cardiovascular mortality in the lowest BMI strata (J-curve).

In March 2018, a study was published by researchers from the University of Glasgow, challenging the obesity-paradox and heating up the debate of this much-discussed topic [1].

Read More

Topics: Clinical trials in Obesity, Treating Diabetes, Clinical Trials in Diabetes

Posted by Dr. Daniela Lamers on Aug 7, 2018 5:09:00 PM
dr-daniela-lamers

Diabetes: A paradigm case for rewarding innovation in value-based healthcare

Chronic diseases in Europe account for 86% of deaths and 77% of disease burden, that impact on functional status and create a tremendous challenge on national economies. Ageing is a main driver of incident chronic diseases, which again trigger physical and mental vulnerability and morbidity. 

Read More

Topics: Treating Diabetes

Posted by Dr. Lars Bochmann on Jul 11, 2018 5:12:00 PM
dr-lars-bochmann

Subscribe to our monthly blog updates

New Call-to-action

Subscribe to Email Updates

Our most popular Posts